This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Pandemics
· Weather
· Hantavirus
Hantavirus vaccine in 2026?
Yes
$111.2K Volume
7%
About This Market
Similar Markets
Measles cases in U.S. in 2026?
↑2k
Yes 99¢No 1¢
↑3k
Yes 82¢No 18¢
Measles cases in U.S. by May 31?
2000
Yes 58¢No 42¢
2200
Yes 2¢No 98¢
Flu Hospitalization Rate Week 20, 2026?
85–90
Yes 98¢No 2¢
90–95
Yes 2¢No 98¢
Which countries will have an Ebola case in 2026?
South Sudan
Yes 79¢No 21¢
United States
Yes 47¢No 53¢
